What is Kratom? How to Use Kratom? Learn About Kratom Benefits in This Detailed Kratom Guide!
What is Kratom?
Kratom, or Mitragyna Speciosa, is a tropical evergreen tree in the coffee (Rubiaceae) tree family. This plant grows naturally in Southeast Asia and is indigenous to Indonesia, Malaysia, Thailand, Papua, New Guinea, and Myanmar. Kratom is available in several strains, primarily green vein, white vein, and red vein. Each strain type is associated with a slightly different alkaloid profile. Green vein and white vein Kratom strains tend to contain more stimulating alkaloids, whereas red vein Kratom strains tend more opioid-agonist type alkaloids. Kratom has been traditionally consumed in the form of fresh leaves (chewing) or in the form of tea. More recently, it has become popular to consume Kratom in the form of finely ground leaf powder, or capsules containing finely ground leaf powder.
The Mitragyna Speciosa tree can grow up to 25 meters high. It has circular leaves that show a heart-shaped base. When the Kratom leaves are fully grown, they are very large.
Kratom leaves contain a myriad of alkaloids, all exerting different effects based on their relative concentrations between the different strains. These alkaloids include mitragynine and 7-hydroxymitragynine, as well as about 25 other alkaloids including rhynchophylline, mitraphylline, ajmalicine, mitragynine pseudoindoxyl, raubasine, and corynantheidine, which is similar to the alkaloids present in Yohimbe bark, and is particularly stimulating in subjective effects.
Kratom has long been used as a traditional medicine in the Southeast Asian countries where it originated. Aside from red vein Kratom strains which are predominantly relaxing, sedating, and pain relieving, there is a unique bell-curve effect with green vein and white vein Kratom strains. Based on available subjective use-case reports and data, this bell-curve effect suggests that stimulation occurs when consumed in lower amounts, whereas calming, pain relieving, and reported euphoric effects occur when consumed in larger amounts.
As Kratom has become more popular and available across the world, many people report to use it in place of prescription pain medications or to assist with opioid withdrawal.
Kratom leaves have been utilized by Southeast Asian people and specialists for a very long time. The stimulant effect was sought after by laborers who required increased energy, stamina, reduced fatigue, and elevated mood to assist in their demanding physical work. Currently, some Southeast Asian nations prohibit Kratom possession and consumption.
To summarize, Kratom is said to provide many benefits. The strain chosen and its relative alkaloid profile help determine what effects that particular Kratom strain will have.
Reported Therapeutic Kratom Benefits:
- Improve intellectual capacity and focus.
- Improve sense of well-being and mood.
- Improve stamina and energy.
- Relieve pain and relax the muscle.
- Assist in sedation and help with insomnia.
- Reduce anxiety.
- Assist in withdrawal from prescription or illicit opioids.
How to Use Kratom?
Traditionally, the leaves of the Kratom tree were either chewed fresh, or dried and formed into tea. More commonly now, Kratom is consumed in finely powdered dry leaf powder, or encapsulated dry leaf powder.
Modern technology and research into Kratom have allowed companies like ELV Bioscience to produce a precision full spectrum alkaloid extract from Kratom dried and powdered Kratom leaves.
Hassan, Z; Muzaimi, M; Navaratnam, V; Yusoff, N. H; Suhaimi, F. W; Vadivelu, R; Vicknasingam, B. K; Amato, D; von Hörsten, S; Ismail, N. I; Jayabalan, N; Hazim, A. I; Mansor, S. M; Müller, C. P (2013). “From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction”. Neuroscience & Biobehavioral Reviews. 37 (2): 138–51. doi:10.1016/j.neubiorev.2012.11.012. PMID 23206666.
“Kratom profile (chemistry, effects, other names, origin, mode of use, other names, medical use, control status)”. Page last updated 8 January 2015: European Monitoring Centre for Drugs and Drug Addiction. Retrieved 12 September 2016.
“Mitragyna speciosa”. Germplasm Resources Information Network (GRIN). Agricultural Research Service (ARS), United States Department of Agriculture (USDA). Retrieved 2013-12-26.
Adkins, Jessica E.; Edward W. Boyer; Christopher R. McCurdy (2011-05-01). “Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity”. Current Topics in Medicinal Chemistry. 11 (9): 1165–75. doi:10.2174/156802611795371305. PMID 21050173.
Fluyau, D; Revadigar, N (2017). “Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom”. Frontiers in Psychiatry. 8: 62. doi:10.3389/fpsyt.2017.00062. PMC 5402527. PMID 28484399.
White CM (2017). “Pharmacologic and clinical assessment of kratom”. Am J Health Syst Pharm (Review). 75 (5): 261–267. doi:10.2146/ajhp161035. PMID 29255059.
Cinosi, E; Martinotti, G; Simonato, P; Singh, D; Demetrovics, Z; Roman-Urrestarazu, A; Bersani, F. S; Vicknasingam, B; Piazzon, G; Li, J. H; Yu, W. J; Kapitány-Fövény, M; Farkas, J; Di Giannantonio, M; Corazza, O (2015). “Following “the Roots” of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries”. BioMed Research International. 2015: 1–11. doi:10.1155/2015/968786. PMC 4657101. PMID 26640804.
Tanguay, Pascal (April 2011). “Kratom in Thailand: Decriminalisation and Community Control?” (PDF). Transnational Institute. “Young people feel the need to drink 4×100 in hidden settings due to fears of arrest by law enforcement. In one district, 21 of 39 villages reported the presence of 4×100 users in their community. Compared to traditional use, 4×100 users are subject to some measure of community discrimination, though community perceptions are far milder than for yaba or heroin users.”
Eisenman, Sasha W. (2014). “Chapter 5. The Botany of Mitragyna speciosa (Korth.) Havil. and Related Species”. In Raffa, Robert B. (ed.). Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium. CRC Press. pp. 57–76. ISBN 978-1-4822-2519-8.
Beckett, Jaclyn R. (2014). “Non-Analgesic CNS Effects”. In Raffa, Robert B. (ed.). Kratom and other mitragynines : the chemistry & pharmacology of opioids from. CRC Press. pp. 195–204. ISBN 9781482225181.
Singh, Darshan; Narayanan, Suresh; Vicknasingam, Balasingam (September 2016). “Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature”. Brain Research Bulletin. 126 (Pt 1): 41–46. doi:10.1016/j.brainresbull.2016.05.004. PMID 27178014.
Suhaimi FW, Yusoff NH, Hassan R, Mansor SM, Navaratnam V, Müller CP, Hassan Z (2016). “Neurobiology of Kratom and its main alkaloid mitragynine”. Brain Res Bull. Mar 25 (Pt 1): 29–40. doi:10.1016/j.brainresbull.2016.03.015. PMID 27018165.
Takayama, Hiromitsu; et al. (2002). “Studies on the Synthesis and Opioid Agonistic Activities of Mitragynine-Related Indole Alkaloids: Discovery of Opioid Agonists Structurally Different from Other Opioid Ligands”. Journal of Medicinal Chemistry. 45 (9): 1949–56. doi:10.1021/jm010576e. PMID 11960505.
Kruegel AC, Grundmann O (2017). “The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse”. Neuropharmacology. 134 (A): 108–20. doi:10.1016/j.neuropharm.2017.08.026. PMID 28830758.
Prozialeck, WC; Jivan, JK; Andurkar, SV (2012). “Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic, and opioid-like effects”. The Journal of the American Osteopathic Association. 112 (12): 792–99. PMID 23212430.
Stapleton, Christine (September 29, 2016). “Congress members ask DEA not to ban kratom: opioid research needed”. Palm Beach Post.
Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D, Koyama F, Matsumoto K, Moriyama T, Yamamoto LT, Watanabe K, Murayama T, Horie S (2002). “Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands”. J. Med. Chem. 45 (9): 1949–56. doi:10.1021/jm010576e. PMID 11960505.
White, CM (1 March 2018). “Pharmacologic and clinical assessment of kratom”. American Journal of Health-System Pharmacy. 75 (5): 261–267. doi:10.2146/ajhp161035. PMID 29255059.
Le D, Goggin MM, Janis GC (2012). “Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom”. Journal of Analytical Toxicology. 36 (9): 616–25. doi:10.1093/jat/bks073. PMID 23024321.
“Psychoactive Substances Act 2016”. The National Archives, HM Government Publishing. 9 September 2016.
“Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7-Hydroxymitragynine Into Schedule I: A Proposed Rule by the Drug Enforcement Administration on 10/13/2016”. Federal Register. Drug Enforcement Administration. 2016-10-13. Retrieved 2016-10-18.